• HTA78 Health Technology Assessment (HTA) Key Drivers for Oral Oncology Products: Comparison Between Brazil and European Countries

    Dec 1, 2024, 00:00

  • HPR80 The Socioeconomic Burden of Migraine in Latin America: A Hidden Brake on Economic Growth?

    Dec 1, 2024, 00:00

  • HTA11 Early Access Programs (EAPs) in Fran Reasons for Refusal

    Dec 1, 2024, 00:00

  • EPH244 Adverse Drug Reactions Due to Antitubercular Therapy in Multidrug-Resistant-Tuberculosis in North-East India

    Dec 1, 2024, 00:00

  • CO69 Indirect Treatment Comparison of Iptacopan Versus Eculizumab and Ravulizumab for Patients With Paroxysmal Nocturnal Hemoglobinuria Naive to C5 Inhibitors

    Dec 1, 2024, 00:00

  • EE351 Societal Impact and Economic Burden of Lipodystrophy in Bulgaria

    Dec 1, 2024, 00:00

  • EPH128 COVID-19 Is Here to Stay: Seasonal Endemic SARS-CoV-2 Infection Patterns Indicate Recurring Waves Adding to Respiratory and Cardiovascular Disease Burden in Germany

    Dec 1, 2024, 00:00

  • HTA77 Replicating a Partitioned Survival Model From an ICER Report Using Generative AI

    Dec 1, 2024, 00:00

  • EE294 Evaluating the Economic Burden of Therapeutic Inertia in People With Type 2 Diabetes in Saudi Arabia

    Dec 1, 2024, 00:00

  • HPR103 Recent Developments in European Voluntary Cross-Border Collaborations in Joint HTA, Drug Pricing, Procurement, and Readiness for EU HTA Implementation

    Dec 1, 2024, 00:00

  • EE547 Budget Impact Analysis of Epcoritamab for the Treatment of Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma After Two or More Lines of Systemic Therapy in Greece

    Dec 1, 2024, 00:00

  • P48 Primary Care Resource Utilization and Costs of Imminent Subsequent Fractures in Postmenopausal Women: A Distributed Network Analysis Using Data Mapped to OMOP Common Data Model From Five European Countries

    Dec 1, 2024, 00:00

  • PT32 Economic Evaluation of Abdominal Aortic Aneurysm Screening in the Czech Republic

    Dec 1, 2024, 00:00

  • HTA38 Is There Value in Utilizing Country-Specific Health Utility Values for Health Technology Assessment Submissions? Findings From a Case Study in Hematological Cancers

    Dec 1, 2024, 00:00

  • HTA104 Equity Is Not Equal: A Comparative Study of How Equity Is Considered by NICE, ICER, CDA-AMC, and PBAC

    Dec 1, 2024, 00:00

  • HTA133 Patient Involvement Initiatives in HTAs: How Can We Do Better?

    Dec 1, 2024, 00:00

  • EPH156 Estimated Public Health Impact of Italian Smokers Switching to Smoke-Free Products: A Population Health Impact Modeling Study

    Dec 1, 2024, 00:00

  • HSD60 Can the Use of Andon and a Dedicated Traffic Management Nurse Assist in Diagnosing Operational Issues in Surgical Centers?

    Dec 1, 2024, 00:00

  • EE391 Psychometric Performance of EQ-5D-5L and VILL-UI, a New Condition-Specific Preference-Weighted Measure, in Patients With Age-Related Macular Degeneration: A Macustar Study Report

    Dec 1, 2024, 00:00

  • EE642 Cost-Effectiveness of Febuxostat 120/80 Mg as a Second-Line After Allopurinol 100/300MG in Gout Patients in Algeria

    Dec 1, 2024, 00:00

  • HTA206 For Orphan Drugs Technology Assessments, One Size May Not Fit All: Will the Implementation of JCA Lead to Increased Access or Will It Just Lead to a Duplication of Work?

    Dec 1, 2024, 00:00

  • EPH17 Targeted Literature Review (TLR) on the Mortality in Patients With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) in the USA

    Dec 1, 2024, 00:00

  • EE286 Cost-Effectiveness of Nirmatrelvir/Ritonavir in Swedish Adults, Stratified by Age, Comorbidity and Vaccination Status, Compared to No Anti-Viral Treatment

    Dec 1, 2024, 00:00

  • CO105 Impact of Glucagon-like Peptide 1 Receptor Agonist (GLP-1 RA) Non-Persistence on Body Mass Index, HBA1C, and Lipids: Analysis of Over 190,000 Adults Treated With Semaglutide, Liraglutide, and Tirzepatide in US Real-World Data

    Dec 1, 2024, 00:00

  • HTA198 Precedents for Reimbursed Highly Specialised Technologies Appraised By the National Institute for Health and Care Excellen Key Takeaways and Recommendations

    Dec 1, 2024, 00:00

  • EE553 Model-Projected Clinical Outcomes of Exagamglogene Autotemcel (exa-cel) in Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises in Canada

    Dec 1, 2024, 00:00

  • Cover

    Dec 1, 2024, 00:00

  • EE624 Budget Impact of Intravenous Eptinezumab in the Prevention of Chronic Migraine Patients in United Arab Emirates

    Dec 1, 2024, 00:00

  • EPH223 Trends in Epidemiology and Mortality of Patients With Melanoma in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • CO60 Superior Cardiovascular Benefits of SGLT2 Inhibitors Over DPP4 Inhibitors for Severe Diabetic Kidney Disease: A Population-Based Cohort Study

    Dec 1, 2024, 00:00

  • EE366 The Cost-Effectiveness of Maribavir for Post-Transplant Refractory Cytomegalovirus Infection in France

    Dec 1, 2024, 00:00

  • EE469 Cost-Utility Analysis of Nutrient-Dense Supplementation in Undernourished Children in Indonesia

    Dec 1, 2024, 00:00

  • HTA223 How to Speed Up the Process of Introducing High-Value Innovative Technologies to the Health System: The Catalan Health System Innovation Access Program (PASS)

    Dec 1, 2024, 00:00

  • Enhancing Patient Response to Patient-Reported Outcome Measures: Insights From a Leading Dutch University Hospital

    Dec 1, 2024, 00:00

  • EPH79 Impact of the COVID-19 Pandemic on Diabetes Mellitus Care in Portugal

    Dec 1, 2024, 00:00

  • HPR56 Exploring If a Price Premium Is Requested for Cancer Drugs That Seek Reimbursement on State-Subsidised Schemes in Ireland: An Analysis of Drugs That Have Undergone a Full HTA by the NCPE in Ireland Between 2019 and 2023

    Dec 1, 2024, 00:00

  • EPH224 Trends in Epidemiology and Mortality of Patients With Coronary Heart Disease in Germany: A Retrospective Study Using German Claims Data

    Dec 1, 2024, 00:00

  • EE659 Is Universal Genetic Testing Cost-Effective to Detect and Manage Lynch Syndrome in Singapore?

    Dec 1, 2024, 00:00

  • EE754 Challenges in Identifying Information to Build Economic Evaluations in Hereditary Angioedema

    Dec 1, 2024, 00:00

  • EPH18 Assessment of Cardiovascular Events in Patients With Severe COPD Exacerbations

    Dec 1, 2024, 00:00

  • P41 The Influence of Recall and Timing of Assessment on the Estimation of the QALY When Health Fluctuates Recurrently

    Dec 1, 2024, 00:00

  • EPH273 Retrospective Observational Study on Real-World Adult Patients With Bipolar Disorder: Demographic, Comorbidity, and Drug Prescription Profiles

    Dec 1, 2024, 00:00

  • HSD50 Impact of Hospital Nurse Staffing on Direct Medical Cost and Patient Outcomes in China: A Cross-Sectional Study

    Dec 1, 2024, 00:00

  • EE514 Budget Impact Model for Insulin Glargine-300U/mL (Gla-300) vs Insulin Degludec 100 U/mL in the Treatment of Type 1 Diabetes Mellitus Based on the Inrange Study

    Dec 1, 2024, 00:00

  • EPH41 Incremental Burden Attributable to Exposure to Socio-Environmental Factors on Patients With Lung Cancer in France

    Dec 1, 2024, 00:00

  • Editorial Board

    Nov 5, 2024, 08:49

  • Linking Reimbursement to Patient Benefits for Advanced Therapy Medicinal Products and Other High-Cost Innovations: Policy Recommendations for Outcomes-Based Agreements in Europe

    Nov 1, 2024, 00:00

  • Valuation of Multidimensional Health States With a Bolt-On: Is There a Shortcut? [Editor's Choice]

    Nov 1, 2024, 00:00

  • An Exploratory Study of Alternative Time Frames and Descriptors for EQ-5D-5L in Obstructive Airway Diseases Using Mixed Methods

    Nov 1, 2024, 00:00

  • Table of Contents

    Nov 1, 2024, 00:00

  • When Are You Recovered? Defining Cutoff Points Using the Acute Respiratory Tract Infection Questionnaire

    Nov 1, 2024, 00:00

  • How Many Monte Carlo Samples Are Needed for Probabilistic Cost-Effectiveness Analyses?

    Nov 1, 2024, 00:00

  • Choice Consistency in Discrete Choice Experiments: Does Numeracy Skill Matter?

    Nov 1, 2024, 00:00

  • Development of a Prioritization Framework to Aid Healthcare Funding Decision Making in Health Technology Assessment in Australia: Application of Multicriteria Decision Analysis

    Nov 1, 2024, 00:00

  • EQ-5D-5L Population Scores in Mainland China: Results From a Nationally Representative Survey 2021

    Nov 1, 2024, 00:00

  • Measuring Healthcare Experiences Among People With Intellectual Disability: A Rapid Evidence Synthesis of Tools and Methods

    Nov 1, 2024, 00:00

  • Recommendations on the Use of Structured Expert Elicitation Protocols for Healthcare Decision Making: A Good Practices Report of an ISPOR Task Force [Editor's Choice]

    Nov 1, 2024, 00:00

  • Informing the United States Medicare Drug Price Negotiation for Apixaban and Rivaroxaban: Methodological Considerations for Value Assessments Many Years After Launch

    Nov 1, 2024, 00:00

  • Clinical Outcome Assessments Are Never “Validated” [Editor's Choice]

    Nov 1, 2024, 00:00

  • Attribute Development in Health-Related Discrete Choice Experiments: A Systematic Review of Qualitative Methods and Techniques to Inform Quantitative Instruments [Editor's Choice]

    Nov 1, 2024, 00:00

  • Assessing the Health and Welfare Benefits of Interventions Using the Wider Societal Impacts Framework [Editor's Choice]

    Nov 1, 2024, 00:00

  • Key Issues of Economic Evaluations for Health Technology Assessment in China: A Nationwide Expert Survey

    Nov 1, 2024, 00:00

  • First-Line Treatment With Atezolizumab Plus Bevacizumab and Chemotherapy for US Patients With Metastatic, Persistent, or Recurrent Cervical Cancer: A Cost-Effectiveness Analysis

    Nov 1, 2024, 00:00

  • The Cost-Effectiveness of Germline BReast CAncer Gene Testing in Metastatic Prostate Cancer Followed by Cascade Testing of First-Degree Relatives of Mutation Carriers

    Nov 1, 2024, 00:00

  • Table of Contents

    Oct 1, 2024, 00:00

  • Patient-Reported Outcome Measures as an Intervention: A Comprehensive Overview of Systematic Reviews on the Effects of Feedback

    Oct 1, 2024, 00:00

  • Uncertainty in Long-Term Relative Effectiveness of Medicines in Health Technology Assessment [Editor's Choice]

    Oct 1, 2024, 00:00

  • Remote-Use Applications of the Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised Clinical Outcome Assessment Tool: A Scoping Review

    Oct 1, 2024, 00:00

  • A New and Improved Experimental Design for the Discrete Choice Experiment Module of the EuroQol Valuation Technology Protocol

    Oct 1, 2024, 00:00

  • Do Behavioral Characteristics Influence the Breast Cancer Diagnosis Delay? Evidence From French Retrospective Data

    Oct 1, 2024, 00:00

  • Market Entry Agreements for Innovative Pharmaceuticals Subject to Indication Broadening: A Case Study for Pembrolizumab in The Netherlands [Editor's Choice]

    Oct 1, 2024, 00:00

  • Author Reply

    Oct 1, 2024, 00:00

  • Mapping the Lequesne Functional Index Into the EQ-5D-5L Utility Index in Patients With Knee Osteoarthritis

    Oct 1, 2024, 00:00

  • Predicting the Population Health Economic Impact of Current and New Cancer Treatments for Colorectal Cancer: A Data-Driven Whole Disease Simulation Model for Predicting the Number of Patients with Colorectal Cancer by Stage and Treatment Li ...

    Oct 1, 2024, 00:00

  • Generating Utilities for the Château-Santé Base: A Novel, Generic, and Patient-Centered Health-Outcome Measure

    Oct 1, 2024, 00:00

  • Traditional Methods Hold Their Ground Against Machine Learning in Predicting Potentially Inappropriate Medication Use in Older Adults [Editor's Choice]

    Oct 1, 2024, 00:00

  • Integrating Price Benchmarks and Comparative Clinical Effectiveness to Inform the Medicare Drug Price Negotiation Program [Editor's Choice]

    Oct 1, 2024, 00:00

  • Author Reply

    Oct 1, 2024, 00:00

  • Examining the Impact of Structural Uncertainty Across 10 Type 2 Diabetes Models: Results From the 2022 Mount Hood Challenge

    Oct 1, 2024, 00:00

  • Cost-of/Burden-of-Illness Studies: Steps Backward?

    Oct 1, 2024, 00:00

  • A Tutorial on Value-Based Adaptive Designs: Could a Value-Based Sequential 2-Arm Design Have Created More Health Economic Value for the Big CACTUS Trial? [Editor's Choice]

    Oct 1, 2024, 00:00

  • Does Willingness to Pay Differ for Mental and Physical Health?

    Oct 1, 2024, 00:00

  • Sales Revenues for New Therapeutic Agents Approved by the United States Food and Drug Administration From 1995 to 2014

    Oct 1, 2024, 00:00

  • Guiding Principles for Evaluating Vaccines in Joint Health Technology Assessment in the European Union: Preparing for the European Union’s Regulation on Health Technology Assessment for Vaccines

    Oct 1, 2024, 00:00

  • Editorial Board

    Sep 27, 2024, 09:02

  • Further Evidence of Feasibility, Validity, and Reliability of Quality of Life-Aged Care Consumers: Evidence From Home-Based Care Settings

    Sep 1, 2024, 00:00

  • Facilitators and Barriers in the Implementation and Adoption of Patient-Reported Outcomes Measurements in Daily Practice

    Sep 1, 2024, 00:00

  • A Feasible Estimation of a “Corrected” EQ-5D Social Tariff

    Sep 1, 2024, 00:00

  • Experience Counts: Unveiling Patients’ Willingness to Pay for Remote Monitoring and Patient Self-Measurement

    Sep 1, 2024, 00:00

  • A Roadmap for Improving Medicare’s Application of Coverage With Evidence Development [Editor's Choice]

    Sep 1, 2024, 00:00

  • Documenting the Full Value of Vaccination: A Systematic Review of Value Frameworks [Editor's Choice]

    Sep 1, 2024, 00:00

  • Psychometric Performance of the EQ Health and Wellbeing Short in a United Kingdom Population Sample [Editor's Choice]

    Sep 1, 2024, 00:00

  • A Direct Comparison Between Discrete Choice With Duration and Composite Time Trade-Off Methods: Do They Produce Similar Results?

    Sep 1, 2024, 00:00

  • Qualitative and Psychometric Evaluation of 29-Item Patient-Reported Outcomes Measurement Information System® to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel Disease

    Sep 1, 2024, 00:00

  • Table of Contents

    Sep 1, 2024, 00:00

  • Testing “Pits” Time Trade-Off: Can Data Quality be Improved by Removing Death From Valuation of Health States? [Editor's Choice]

    Sep 1, 2024, 00:00

  • Consolidated Health Economic Evaluation Reporting Standards for Interventions That Use Artificial Intelligence (CHEERS-AI) [Editor's Choice]

    Sep 1, 2024, 00:00

  • A Targeted Review of Worldwide Indirect Treatment Comparison Guidelines and Best Practices

    Sep 1, 2024, 00:00

  • Assessing the Cost-Effectiveness of Next-Generation Sequencing as a Biomarker Testing Approach in Oncology and Policy Implications: A Literature Review

    Sep 1, 2024, 00:00

  • Financial Toxicity of Withdrawn Poly (Adenosine Diphosphate Ribose) Polymerase Inhibitor Indications for Ovarian Cancer

    Sep 1, 2024, 00:00

  • Putting a Dollar Value on Informal Care Time Provided to People Living With Dementia: A Discrete Choice Experiment

    Sep 1, 2024, 00:00

  • Editorial Board

    Aug 27, 2024, 14:04

  • Editorial Board

    Aug 7, 2024, 11:53

  • Illustrating the Financial Consequences of Outcome-Based Payment Models From a Payers Perspective: The Case of Autologous Gene Therapy Atidarsagene Autotemcel (Libmeldy®)

    Aug 1, 2024, 00:00

  • It Takes 2 to Tango. Setting Out the Conditions in Which Performance-Based Risk-Sharing Arrangements Work for Both Parties [Editor's Choice]

    Aug 1, 2024, 00:00

  • Utilization, Expenditure, and Treatment Patterns Associated With Calcitonin Gene-Related Peptide Monoclonal Antibodies Reimbursed Subject to a Managed Access Protocol in Ireland

    Aug 1, 2024, 00:00

  • Table of Contents

    Aug 1, 2024, 00:00

  • The Inflation Reduction Act: An Opportunity to Accelerate Confidence in Real-World Evidence in the United States [Editor's Choice]

    Aug 1, 2024, 00:00

  • Can Generalized Cost-Effectiveness Analysis Leverage Meaningful Use of Novel Value Elements in Pharmacoeconomics to Inform Medicare Drug Price Negotiation?

    Aug 1, 2024, 00:00

  • Economic Evaluations of Chimeric Antigen Receptor T-Cell Therapies for Hematologic and Solid Malignancies: A Systematic Review [Editor's Choice]

    Aug 1, 2024, 00:00

  • Cost-Effectiveness of Axicabtagene Ciloleucel for Adult Patients With Relapsed or Refractory Follicular Lymphoma in the United States

    Aug 1, 2024, 00:00

  • Treatment Effect Waning Assumptions: A Review of National Institute of Health and Care Excellence Technology Appraisals [Editor's Choice]

    Aug 1, 2024, 00:00

  • The Long COVID Symptoms and Severity Score: Development, Validation, and Application

    Aug 1, 2024, 00:00

  • EQ-5D-5L Population Norms for China Derived From a National Health Survey

    Aug 1, 2024, 00:00

  • Navigating Public Policy Responses to a Pandemic: The Balancing Act Between Physical Health, Mental Health, and Household Income

    Aug 1, 2024, 00:00

  • Implementing Multilevel Network Meta-Regression for Time-To-Event Outcomes: A Case Study in Relapsed Refractory Multiple Myeloma

    Aug 1, 2024, 00:00

  • How Do the Institute for Clinical and Economic Review’s Assessments of Comparative Effectiveness Compare With the German Federal Joint Committee’s Assessments of Added Benefit? A Qualitative Study

    Aug 1, 2024, 00:00

  • Estimating the Allocation of the Economic Value Generated by Utilization of All-Oral Direct-Acting Antivirals for Hepatitis C in the United States, 2015 to 2019

    Aug 1, 2024, 00:00

  • A Systematic Review and Quality Assessment of Cardiovascular Disease-Specific Health-Related Quality-of-Life Instruments Part I: Instrument Development and Content Validity

    Aug 1, 2024, 00:00

  • Health Fluctuations in Dementia and its Impact on the Assessment of Health-Related Quality of Life Using the EQ-5D-5L [Editor's Choice]

    Aug 1, 2024, 00:00

  • Validating Health Economic Models With the Probabilistic Analysis Check dashBOARD

    Aug 1, 2024, 00:00

  • The Measurement Properties of the EQ-HWB and the EQ-HWB-S in Italian Population: A Comparative Study With EQ-5D-5L

    Jul 1, 2024, 00:00

  • Testing the Psychometric Properties of 9 Bolt-Ons for the EQ-5D-5L in a General Population Sample [Editor's Choice]

    Jul 1, 2024, 00:00

  • Understanding the Complex Interactions Between Interventions, Well-Being, and Resource Allocation

    Jul 1, 2024, 00:00

  • Challenges of Incorporating Life Cycle Drug Pricing in Cost-Effectiveness Models: A Review of Methods and Modeling Suggestions

    Jul 1, 2024, 00:00

  • From Health to Well-Being: Toward a Monetary Valuation of a Well-Being-Adjusted Life-Year [Editor's Choice]

    Jul 1, 2024, 00:00

  • Hepatitis C Elimination in Rwanda: Progress, Feasibility, and Economic Evaluation

    Jul 1, 2024, 00:00

  • Values Beyond “Health” in Budget-Constrained Healthcare Systems [Editor's Choice]

    Jul 1, 2024, 00:00

  • The Ceiling Effects of EQ-5D-3L and 5L in General Population Health Surveys: A Systematic Review and Meta-Analysis

    Jul 1, 2024, 00:00

  • Cost-Effectiveness of 2 Models of Pessary Care for Pelvic Organ Prolapse: Findings From the TOPSY Randomized Controlled Trial

    Jul 1, 2024, 00:00

  • A Head-to-Head Comparison of EQ-HWB and EQ-5D-5L in Patients, Carers, and General Public in China

    Jul 1, 2024, 00:00

  • Flexible Approaches Based on Multistate Models and Microsimulation to Perform Real-World Cost-Effectiveness Analyses: An Application to Proprotein Convertase Subtilisin-Kexin Type 9 Inhibitors

    Jul 1, 2024, 00:00

  • Construct Validity, Reliability, and Responsiveness of the 10-Item Well-Being Instrument for Use in Economic Evaluation Studies [Editor's Choice]

    Jul 1, 2024, 00:00

  • Table of Contents

    Jul 1, 2024, 00:00

  • Development of a Value Assessment Framework for Pediatric Health Technologies Using Multicriteria Decision Analysis: Expanding the Value Lens for Funding Decision Making

    Jul 1, 2024, 00:00

  • Editorial Board

    Jul 1, 2024, 00:00

  • Tackling Challenges in Assessing the Economic Value of Tumor-Agnostic Therapies: A Cost-Effectiveness Analysis of Pembrolizumab as a Case Study

    Jul 1, 2024, 00:00

  • Subjective Well-Being Population Norms and Inequalities in Hungary: A Large Cross-Sectional, Internet-Based Survey

    Jul 1, 2024, 00:00

  • Comparison of the EQ-HWB and EQ-HWB-S With Other Preference-Based Measures Among United States Informal Caregivers [Editor's Choice]

    Jul 1, 2024, 00:00

  • Social Decision-Making Analysis: A General Approach to Inform Decisions on Resources in the Public Sector [Editor's Choice]

    Jul 1, 2024, 00:00

  • Methods for Including Adverse Events in Economic Evaluations: Suggestions for Improvement

    Jul 1, 2024, 00:00

  • Anti–Vascular Endothelial Growth Factor Drugs Compared With Panretinal Photocoagulation for the Treatment of Proliferative Diabetic Retinopathy: A Cost-Effectiveness Analysis

    Jul 1, 2024, 00:00

  • Editorial Board

    Jun 12, 2024, 08:53

  • HTA6 Use of Medical Device Assessment Criteria in CONITEC Evaluations

    Jun 1, 2024, 00:00

  • HSD121 Real-World Prescribing of Tirzepatide Labeled for Obesity in the United States

    Jun 1, 2024, 00:00

  • PCR165 Health-Related Quality of Life of Type 1 Diabetes and Severe Hypoglycemia in Adult Continuous Glucose Monitor Users: Results From a Cross-Sectional Survey in the United States

    Jun 1, 2024, 00:00

  • RWD166 Evaluation of the One-Day Surgical Performance of the Hungarian Universities in the Obstetrics and Gynecology Medical Field

    Jun 1, 2024, 00:00

  • EE293 A Framework to Assess Uncertainties of Polygenic Risk Scores in Disease Screening and Prevention in Cost-Effectiveness Analyses

    Jun 1, 2024, 00:00

  • EPH213 Burden of Heart Failure After Hospitalization for Myocardial Infarction in the United States: A Targeted Literature Review

    Jun 1, 2024, 00:00

  • HTA34 Cost-Effectiveness Analysis of Icosapent Ethyl (IPE) for the Reduction of the Severe Hypertriglyceridemia (HTG) in China

    Jun 1, 2024, 00:00

  • EE19 Cost-Effectiveness Analysis of Infliximab, Adalimumab, and Certolizumab for Crohn's Disease: A Markov Model Study

    Jun 1, 2024, 00:00

  • MT15 Postoperative Clinical and Economic Outcomes of Patients With Reverse or Anatomic Total Shoulder Arthroplasty at One Year: A Retrospective, United States Hospital Billing Database Analysis

    Jun 1, 2024, 00:00

  • PCR188 Compliance and Design Features of Electronic Participant-Reported Dosing Diaries

    Jun 1, 2024, 00:00

  • Patient-Centered Research

    Jun 1, 2024, 00:00

  • SA28 Using Linked Claims-EHR Data: The Added Value When Assessing Comorbidity Burden Among Patients With Asthma

    Jun 1, 2024, 00:00

  • CO70 Comparative Bayesian Network Meta-Analysis of BTKi-Specific Adverse Events in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia

    Jun 1, 2024, 00:00

  • SA24 CHIME2 (Chinese Hong Kong Integrated Modeling and Evaluation): An Updated Model to Simulate Lifetime Health Outcomes of Patients with Type 2 Diabetes

    Jun 1, 2024, 00:00

  • RWD192 Real-World Use of Tirzepatide Among People Without Evidence of Type 2 Diabetes: Results From Merative Marketscan Commercial Database

    Jun 1, 2024, 00:00

  • MSR9 Can Artificial Intelligence Tools Enhance Data Abstraction During Systematic Literature Reviews?

    Jun 1, 2024, 00:00

  • HSD1 Assessing Community Pharmacist Expectation, Satisfaction, and Intentions in the Wasfaty E-Servi Using the Expectation Conformation Theory

    Jun 1, 2024, 00:00

  • EE353 An Analysis of Stakeholders’ Contribution to High-WAC and Low-WAC Adalimumab Products in 2025 Under the Inflation Reduction Act in the United States

    Jun 1, 2024, 00:00

  • CO91 Systemic Therapy Eligibility Criteria of the International Psoriasis Council (IPC) May Reduce Undertreatment of PsO Patients with Low Body Surface Area Involvement Associated with High Disease Burden

    Jun 1, 2024, 00:00

  • PCR196 Psychometric Validation of the PROMIS Fatigue-Short Form 7A in Adults with Newly Diagnosed or Recurrent Mycobacterium avium Complex (MAC) Lung Disease: The ARISE and ENCORE Studies

    Jun 1, 2024, 00:00

  • EE485 Cost-Effectiveness of Active Surveillance for Incidentally Detected Early-Staged Papillary Thyroid Cancer: A Microsimulation Study

    Jun 1, 2024, 00:00

  • P7 Costs and Health Care Resource Utilization Associated with Negative Symptoms Among Patients with Schizophrenia in the United States

    Jun 1, 2024, 00:00

  • CO26 Targeted Literature Review Exploring Burden of Disease in Junctional and Dystrophic Epidermolysis Bullosa

    Jun 1, 2024, 00:00

  • EPH226 Associations between Antimicrobial Susceptibility of Streptococcus Pneumoniae and Disease Severity Outcomes in Older Adults with Invasive Pneumococcal Disease in Sao Paulo, Brazil

    Jun 1, 2024, 00:00

  • EPH108 Clopidogrel Resistance in Patients With Recurrent Ischaemic Stroke on Dual Antiplatelet Therapy and Its Economic Impact in a Lower-Middle Income Country: A Single Centered Study in Southern India

    Jun 1, 2024, 00:00

  • RWD157 Objective Fit-4-Purpose Assessment of Real-World Data for Evidence Generation in Type 2 Diabetes Mellitus: A Trial Tokenization Approach

    Jun 1, 2024, 00:00

  • HTA11 Manufacturer Engagement and Revision Outcomes in the “Phase Contradictoire” of the HTA Process in Fran A Descriptive Analysis

    Jun 1, 2024, 00:00

  • RWD158 Assessing RSV Vaccination Trends in the Context of Seasonal RSV Diagnoses Using Near Real-Time Administrative Claims

    Jun 1, 2024, 00:00

  • RWD3 Review of the Use of Electronic Health Records for Advancing Schizophrenia Research in the UK

    Jun 1, 2024, 00:00

  • Advancing the Use of Patient Reported Outcomes

    Jun 1, 2024, 00:00

  • EPH132 Adverse Drug Reaction-Related Hospital Admission in Older Australians With Dementia

    Jun 1, 2024, 00:00

  • HPR100 Health Technologies Value Assessment Through the Lens of Health Equity; How Far From Being Incorporated Routinely? An Environmental Scan of Health Equity Frameworks and Policy Gaps

    Jun 1, 2024, 00:00

  • EE307 Economic Evaluation of a Screening Programme for Diabetes, Hypertension and Hyperlipidaemia in Middle-Aged Adults in Hong Kong: A Simulation Analysis

    Jun 1, 2024, 00:00

  • EPH147 Socioeconomic Burden of Ischemic Heart Diseases in the Japanese Healthcare System – A System Dynamics Simulation for Policy Decision-Making

    Jun 1, 2024, 00:00

  • EE288 Decision Model to Evaluate the Cost of Clinical Events Associated with Switching from Apixaban to Rivaroxaban Among Patients with Non-Valvular Atrial Fibrillation in Germany

    Jun 1, 2024, 00:00

  • EE510 Navigating Economics of Telehealth in Oncology

    Jun 1, 2024, 00:00

  • MT36 Assessment and Comparison of the Manual Steps Required to Perform Whole Blood Processing Using a Semi-Automated Method Versus a Fully Automated Method

    Jun 1, 2024, 00:00

  • HTA28 Comparative Analysis of Orphan Drug HTA Assessment: Perspectives from HAS and SMC

    Jun 1, 2024, 00:00

  • EE490 Utilization and Costs of Patients With Type-2 Diabetes and Cardiovascular Disease Treated With Sodium Glucose Cotransporter-2 Inhibitors and Glucagon Like Peptide-1 Receptor Agonists

    Jun 1, 2024, 00:00

  • EPH183 The Association Between the Minority Health Social Vulnerability Index and Pneumococcal Disease Incidence Among Medicare Beneficiaries (2016-2019)

    Jun 1, 2024, 00:00

  • RWD183 Experience in Implementing Clinical Trial to Real-World Data (RWD) Linkage

    Jun 1, 2024, 00:00

  • MSR35 Item Performance and Structural Validity of the Quick Motor Function Test Among Late Onset Pompe Disease Patients

    Jun 1, 2024, 00:00

  • EE132 Economic Outcomes and Real-World Adherence of Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises Treated With L-Glutamine, Voxelotor, and Crizanlizumab in the United States

    Jun 1, 2024, 00:00

  • PT44 Prevalence of Comorbidities and Hospitalization in the 65 and over SLE (SYSTEMIC LUPUS ERYTHEMATOSUS) Patient Population: A Comparative Analysis of the FORWARD Lupus Registry and Medicare Data in the US (2017-2021)

    Jun 1, 2024, 00:00

  • EE164 A Systematic Review and Meta-Analysis of Economic Burden of Breast Cancer Among Adult Females: Based on the Perspective of Social Development Level and Progression of Disease

    Jun 1, 2024, 00:00

  • RWD96 Risk of Venous Thromboembolism with Janus Kinase Inhibitors in Rheumatoid Arthritis: A Systematic Review

    Jun 1, 2024, 00:00

  • HSD16 Understanding Causes and Consequences in the Operating Room Associated with Distractions, Interruptions, and Disruptions: A Focused Literature Review

    Jun 1, 2024, 00:00

  • RWD54 Comparative Analysis of Different Methods of Disease Progression Data Capture in Patients With Metastatic Castration-Resistant Prostate Cancer

    Jun 1, 2024, 00:00

  • MSR58 Comparing Predictive Models: Traditional Versus Modern Statistical Approaches for Economic Outcomes in Major Depressive Disorder

    Jun 1, 2024, 00:00

  • EE369 Healthcare Resource Utilization Among Patients With Sickle Cell Disease With Recurrent Vaso-Occlusive Crises in Canada

    Jun 1, 2024, 00:00

  • EE151 Clinical and Economic Benefits of Adjuvanted and High-Dose Influenza Vaccines in the Elderly in Argentina

    Jun 1, 2024, 00:00

  • PCR62 Household Costs for Home, Vehicle, and Medical Equipment Expenditures to Accommodate Functional Impairments for Individuals with Duchenne Muscular Dystrophy

    Jun 1, 2024, 00:00

  • CO115 Long-Term Post-Recurrence Survival (PRS) Outcomes for Stage IIB/C Melanoma Patients in Real-World (RW) Settings: Analyses from a Longitudinal Electronic Health Record Database in the United States

    Jun 1, 2024, 00:00

  • CO81 Cyclosporine Ophthalmic Solution 0.09% Improves the Signs and Symptoms of Dry Eye Disease in Patients Whose Disease Is Inadequately Controlled on Cyclosporine Ophthalmic Emulsion 0.05%

    Jun 1, 2024, 00:00

  • HPR96 Racial Disparity and Awareness of Disease-Risk Genetic Testing: A Nationwide Sampling Survey Analysis

    Jun 1, 2024, 00:00

  • EPH107 Characteristics of the COVID-19 Epidemic in Three Hungarian Disctricts

    Jun 1, 2024, 00:00

  • EE333 Budget Impact of Oral Nirmatrelvir/Ritonavir in Patients at High Risk for Progression to Severe COVID-19 in the U.S.: An Updated Analysis

    Jun 1, 2024, 00:00

  • Clinical Outcomes

    Jun 1, 2024, 00:00

  • Psychometric Properties of the EQ-5D-Y-5L for Children With Intellectual Disability

    Jun 1, 2024, 00:00

  • HSD51 Evaluation of the Healthcare System Burden Associated With Intravenous Treatment for Paroxysmal Nocturnal Hemoglobinuria

    Jun 1, 2024, 00:00

  • PCR103 Young People’s Preferences Towards Web-Based Mental Health Interventions for Anxiety and Depression: A Discrete Choice Experiment

    Jun 1, 2024, 00:00

  • PCR81 Association between Video Gaming Habits and Psychological Distress Among Adolescents

    Jun 1, 2024, 00:00

  • EPH73 Clinical Characteristics of Patients in the Intensive Care Unit with Infections Caused By Multiresistant Gram-Negative Bacteria

    Jun 1, 2024, 00:00

  • MT23 The Changing Healthcare Landscape of Lumbar Spinal Fusion: Two-Year Claims Database Analysis

    Jun 1, 2024, 00:00

  • PCR5 Perceptions, Experiences, and Behaviors of Patients and Their Caregivers With Gastric and Gastroesophageal Cancer Treated With or Without Trastuzumab Deruxtecan (T-DXd) in the United States

    Jun 1, 2024, 00:00

  • HPR89 Trends in Hospital Charging Practices from 2019-2022 Among Hospitals with and without Chimeric Antigen Receptor (CAR) T-Cell Therapy Utilization

    Jun 1, 2024, 00:00

  • EE76 Anterior-Based Muscle-Sparing Approach (ABLE) Is Cost-Effective When Compared with Posterolateral and Direct Anterior Approaches for Total Hip Arthroplasties

    Jun 1, 2024, 00:00

  • RWD146 Characterization of Chronic Kidney Disease Patients By eGFR Status Using Health Insurance Claims Linked to Lab Testing Data

    Jun 1, 2024, 00:00

  • CO42 Disease Burden of Anal Carcinoma in Chinese Male Patients Under Current Care: A Model Simulation Study

    Jun 1, 2024, 00:00

  • CO137 Are Standard Indirect Treatment Comparison Methods Suitable to Compare First-Line Vs Maintenance Therapies? An Assessment of Enfortumab Vedotin + Pembrolizumab Vs Avelumab in Locally Advanced/Metastatic Urothelial Carcinoma

    Jun 1, 2024, 00:00

  • PCR258 Work Productivity and Activity Impairment Associated with Generalized Anxiety Disorder Among Adults in the United States

    Jun 1, 2024, 00:00

  • HSD45 Effectiveness of Aseptic and Disinfection Measures in Dental Offices in Barranquilla, Colombia

    Jun 1, 2024, 00:00

  • HSD106 Metastatic Colorectal Cancer (mCRC) Patients Treated with Later Lines of Treatment (LOT): A Retrospective Analysis By Race and Ethnicity in the United States (US) Community Oncology Setting

    Jun 1, 2024, 00:00

  • PCR48 Health-Related Quality of Life for Disease-Modifying Therapies Among Patients With Spinal Muscular Atrophy in Taiwan

    Jun 1, 2024, 00:00

  • RWD97 Real-World Disease Burden of Fibrodysplasia Ossificans Progressiva in China

    Jun 1, 2024, 00:00

  • EE501 Estimating the Impact of Delayed Treatment for Major Depressive Disorder Using a Continuous-Time Patient-Level Simulation Model

    Jun 1, 2024, 00:00

  • EPH19 Opioid-Related Overdose Death Rates in the US From 2005 to 2021

    Jun 1, 2024, 00:00

  • PCR64 Examining the Disability Paradox and Health State Utility Valuation in Achondroplasia

    Jun 1, 2024, 00:00

  • EE182 Mepolizumab Impact on Healthcare Resource Utilization and Work Productivity in Patients with Severe Asthma: REALITI-A 2-Year Analysis

    Jun 1, 2024, 00:00

  • SA68 Assessment of Real-World Data Sources and a Hybrid Approach in Real-World Evidence Generation Using Unharmonized Data Sources

    Jun 1, 2024, 00:00

  • PT20 Gleaning Novel Insights from Real World Data: A Machine-Learning Guided Analytical Framework

    Jun 1, 2024, 00:00

  • EE463 A Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab (NIVO+IPI) Vs Pembrolizumab Plus Axitinib (PEM+AXI) for the First-Line Treatment of Intermediate or Poor (I/P)-Risk Advanced Renal Cell Carcinoma Patients in Peru

    Jun 1, 2024, 00:00

  • HPR88 Variation in State Medicaid Use of Brand-over-Generic Preferred Drug Lists

    Jun 1, 2024, 00:00

  • MSR99 A Stacked Ensemble Approach for Building Composite Measure Models in Healthcare

    Jun 1, 2024, 00:00

  • HTA76 Insights into Health Technology Reassessment in Fran A Comprehensive Analysis of Key Outcomes and Manufacturers Engagement (2022-2023)

    Jun 1, 2024, 00:00

  • CO50 Benefit and Risk of Oral Anticoagulant Initiation Strategies in Patients With Atrial Fibrillation and Cancer: A Target Trial Emulation Using the SEER-Medicare Database

    Jun 1, 2024, 00:00

  • EE128 Customer Service Analytics Improve Health Outcomes at Blue Cross and Blue Shield of Louisiana

    Jun 1, 2024, 00:00

  • EE274 Cost-Effectiveness Analysis of Large-Scale Screening for Celiac Disease in the Pediatric Population

    Jun 1, 2024, 00:00

  • MSR52 Assessing the Representativeness of Provider Encounter Data From a Large Claims Database on Adults With Major Depression

    Jun 1, 2024, 00:00

  • MSR14 Multi-Output Learning for Rare Event Analysis

    Jun 1, 2024, 00:00

  • EPH153 Screening Interval for Colonoscopic Screening for Colorectal Cancer: A Systematic Review of Interval Cancer Rates of Colonoscopic Screening for Colorectal Cancer

    Jun 1, 2024, 00:00

  • PCR209 Joint Modeling of Progression-Free Survival (PFS) and Patient-Reported Symptoms Among Relapsed/Refractory Multiple Myeloma (RRMM) Patients

    Jun 1, 2024, 00:00

  • HSD31 Analyzing Factors Affecting Length of Emergency Department Stay in Patients With Hemophilia

    Jun 1, 2024, 00:00

  • HPR125 Novel Drug Approvals By the U.S. Food and Drug Administration in Rare Diseases: Findings from 2020–2023

    Jun 1, 2024, 00:00

  • HPR111 Disease Burden and Medical Insurance Expenditure of National Price-Negotiated Drugs for Multiple Sclerosis Under Dual-Channel Model in China: A Budget Impact Model

    Jun 1, 2024, 00:00

  • EE8 Targeted Literature Review for Estimating Median Age of Causal Human Papilloma Virus Infection to Oropharyngeal Cancer

    Jun 1, 2024, 00:00

  • CO180 Newer Glucose-Lowering Drugs and Risk of Depression: A Meta-Analysis of Randomized Outcome Trials

    Jun 1, 2024, 00:00

  • RWD53 An Inflection Point in Real-World Treatment Intensification for Men With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) in the United States (US): Results From Patient Chart Reviews

    Jun 1, 2024, 00:00

  • EPH127 Association of Marijuana Use With Poor Mental Health Among Non-Institutionalized Adults in the US

    Jun 1, 2024, 00:00

  • HTA18 Heading into the Unknown: How Will JCA Implementation Affect Global Launch Strategies?

    Jun 1, 2024, 00:00

  • HTA27 An Analysis of Manufacturer and Patient Engagement with Institute for Clinical and Economic Review Assessments

    Jun 1, 2024, 00:00

  • PCR50 Estimating Meaningful Change Thresholds (MCTs) for EORTC Scales in a Phase 3 Trial in Participants With Inoperable or Metastatic Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer

    Jun 1, 2024, 00:00

  • MT42 Evaluation of a Novel Single-Use Ureteroscope: User Satisfaction Comparison Survey

    Jun 1, 2024, 00:00

  • PCR66 Improving Quality of Life in Endometriosis Patients: A Study on Lifestyle and Pain Scores

    Jun 1, 2024, 00:00

  • HPR141 Model Analysis on Budget Impact and Patients’ Burden of National Price-Negotiated Drugs and Different Reimbursement Payment Modes in China: Hyperkalemia As an Example

    Jun 1, 2024, 00:00

  • HPR129 Real-World Policy Effects of Implementing Multi-Gene Panel Sequencing for Advanced Cancers in British Columbia, Canada: An Interrupted Time Series Analysis

    Jun 1, 2024, 00:00

  • CO200 Gender Differences in Clinician-Recorded Side Effects Among People With First Episode Psychosis: Real-World Evidence From Electronic Health Record Data

    Jun 1, 2024, 00:00

  • EE366 Healthcare Costs Comparison of Dupilumab Vs. Omalizumab, Benralizumab and Mepolizumab in Patients with Moderate-to-Severe Asthma: A US Payer Perspective

    Jun 1, 2024, 00:00

  • PCR199 Advancing Patient-Centered Outcomes Research for Rare Diseases: A Mixed-Methods Approach

    Jun 1, 2024, 00:00

  • CO3 Prediction of Long-Term Factor IX Durability Among Hemophilia B Patients Treated with Fidanacogene Elaparvovec Gene Therapy

    Jun 1, 2024, 00:00

  • HPR80 Moving Towards Inclusion: A Review of Access to Oncologic Therapies in the Light of Global Efforts to Advance Gender Equality

    Jun 1, 2024, 00:00

  • CO141 Situation Report: Health Status of Hungarian Ambulance Workers in the COVID Era

    Jun 1, 2024, 00:00

  • EE87 Time-Driven Activity Based Costing of Advanced Ovarian Cancer From the Perspective of a Brazilian Public Hospital

    Jun 1, 2024, 00:00

  • P60 Evaluating Dynamic Treatment Using a Target Trial: The Real-World Effectiveness of Adding Oral Selexipag to a Double Oral Therapy for the Treatment of Patients With Pulmonary Arterial Hypertension

    Jun 1, 2024, 00:00

  • SA2 A Unique Approach for Identifying Thoracic Endovascular Aortic Repair Stent Graft Landing Zones 0/1/2 Using Revascularization Procedure Codes from a Commercial Claims Database

    Jun 1, 2024, 00:00

  • HPR105 Breadth of Patient and Stakeholder Input in CMS's Drug Price Negotiation Program: A Content Analysis of the 2023 Patient-Focused Listening Sessions

    Jun 1, 2024, 00:00

  • CO13 A Claims Analysis To Characterize All-Cause Mortality in Patients With Generalized Pustular Psoriasis in the United States

    Jun 1, 2024, 00:00

  • CO146 Treatment Use and Overall Survival of Patients with Unresectable/Metastatic Melanoma in Colombia: A Real World Study

    Jun 1, 2024, 00:00

  • EE148 The Institutional Level Impact of Additional Apheresis Days for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation on Costs and Healthcare Resource Utilization

    Jun 1, 2024, 00:00

  • CO160 Relationship between Loss of Ambulation (LoA), Disease Burden, and Physical Functioning Among Boys with Duchenne Muscular Dystrophy (DMD)

    Jun 1, 2024, 00:00

  • CO41 Comparative Effectiveness of Glucagon-like Peptide 1 Agonists Vs Dipeptidyl Peptidase 4 Inhibitors on Liver Outcomes in Patients with Type 2 Diabetes and Metabolic Dysfunction-Associated Fatty Liver Disease

    Jun 1, 2024, 00:00

  • EPH149 Regional Dynamics and Prevalence of COVID-19 Variants in US Health and Human Services Regions

    Jun 1, 2024, 00:00

  • RWD87 Real-World Treatment Patterns, Healthcare Costs, and Healthcare Resource Utilization in Patients in the US With Metastatic Non-Small Cell Lung Cancer Receiving Systemic Anticancer Therapy

    Jun 1, 2024, 00:00

  • MSR53 Estimands in EQ-5D-5L: How to Deal with the “Worse Than Death” and the Intercurrent Events of “Death”

    Jun 1, 2024, 00:00

  • PCR49 Mapping and Linking between the EQ-5D-5L and the PROPr in the United States

    Jun 1, 2024, 00:00

  • EE514 Private Hospital Acute Stroke Care Costs: Patient's Viewpoint

    Jun 1, 2024, 00:00

  • EE437 Evaluating Various Predictors Suspected of Influencing Biosimilar Market Share in the U.S.

    Jun 1, 2024, 00:00

  • HTA63 The Role and Implementation of Patient and Public Involvement in Health Technology Assessment: A Systematic Search and Implications for Japan

    Jun 1, 2024, 00:00

  • EE528 Comparative Effectiveness Modeling of an Anti-Pd-1 Antibody Drug Intervention for Patients With Extensive-Stage Small Cell Lung Cancer (ES-SCLC) in the U.S.

    Jun 1, 2024, 00:00

  • MSR83 Predicting Optimal Treatment Regimen to Improve Outcomes of Patients With CLL/SLL Using Random Survival Forest

    Jun 1, 2024, 00:00

  • HPR109 Evaluation of Evidence Informing Medicare’s Coverage With Evidence Development Decision Updates

    Jun 1, 2024, 00:00

  • CO108 The Effect of Approved Anti-Obesity Medications in Patients With Alcohol and Substance Abuse Disorder

    Jun 1, 2024, 00:00

  • HPR77 CMS Coverage Lift on PET Beta Amyloid Imaging Impact on mAb Treatment and Beneficiary Out-Of-Pocket Spending

    Jun 1, 2024, 00:00

  • SA72 Health System As an Adaptative Complex System for Open Innovation

    Jun 1, 2024, 00:00

  • EE252 Economic Impact of Relapses in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD): A Systematic Literature Review

    Jun 1, 2024, 00:00

  • PCR192 Using Linked Claims and EHR Real-World Data to Determine Medication Adherence Among Common Therapeutic Areas of Chronic Disease

    Jun 1, 2024, 00:00

  • MSR18 Improving the Performance of Generative AI to Achieve 100% Accuracy in Data Extraction

    Jun 1, 2024, 00:00

  • CO8 Leading Predictors of Incident Hypertension Among Patients with Cancer in Community Health Centers: A Machine Learning Approach with Shapley Additive Explanations Using Electronic Health Records

    Jun 1, 2024, 00:00

  • EPH130 Mortality Related with Respiratory Syncytial Virus (RSV) Specific and Unspecified Acute Bronchiolitis in Under 2 Years in Colombia, 2012-2021

    Jun 1, 2024, 00:00

  • MSR57 Transforming Systematic Literature Reviews: Unleashing the Potential of GPT-4: A Cutting-Edge Large Language Model, to Elevate Research Synthesis

    Jun 1, 2024, 00:00

  • HSD113 Treatment Patterns, Comorbidities, Healthcare Resource Utilization and Related Costs of Dermatomyositis and Polymyositis in the United States: A Cohort Study in the Merative™ MarketScan® Database

    Jun 1, 2024, 00:00

  • EPH8 Comparison of Patient Identification Methodologies in Chronic Inflammatory Demyelinating Polyneuropathy Using United States Administrative Claims Data

    Jun 1, 2024, 00:00

  • MT47 Navigating the Roadblocks: Identifying the Complexities and Challenges of Artificial Pancreas in Management of Type 1 Diabetes Mellitus

    Jun 1, 2024, 00:00

  • EE387 Healthcare Resource Utilization for Patients With Alzheimer's Disease Versus Non-Alzheimer's Disease Controls in Israel

    Jun 1, 2024, 00:00

  • MSR36 Current Applications of Machine Learning for Causal Inference in Healthcare Research Using Observational Data

    Jun 1, 2024, 00:00

  • SA39 Exploring the Landscape of Genetically Modified Natural Killer Cell (GMNKC) Therapies: A Review of Clinical Trials Indexed on ClinicalTrials.gov

    Jun 1, 2024, 00:00

  • Real-World Data Information Systems

    Jun 1, 2024, 00:00

  • SA54 Expanding the Horizon of Cost-Effectiveness Analysis: A Comprehensive Review of Alternative Methods

    Jun 1, 2024, 00:00

  • PCR228 Healthcare Provider Preferences for Attributes of Influenza Vaccines in the United States: Results From a Discrete-Choice Experiment Study

    Jun 1, 2024, 00:00

  • EPH176 Comparison of Superoxide Dismutase Activities (Mn-SOD AND Cu/Zn-SOD) in Patients Infected with Dengue Virus or Zika Virus

    Jun 1, 2024, 00:00

  • RWD165 Burden of Illness of Intrauterine Adhesions Following Intrauterine Procedures: A Retrospective Analysis of Real-World Data

    Jun 1, 2024, 00:00

  • EE118 Impact of Different Thresholds on Recommendations Made Through Cost-Effectiveness Studies: An Example From Chronic Lymphocytic Leukemia

    Jun 1, 2024, 00:00

  • HTA75 Utilization of Artificial Intelligence By Health Technology Assessment Agencies to Improve Efficiency of Health Technology Appraisals

    Jun 1, 2024, 00:00

  • HPR91 Public Sector Replacement of Privately Funded Pharmaceutical RD: Cost and Efficiency Considerations

    Jun 1, 2024, 00:00

  • HPR54 The European Health Data Space (EHDS): Probable Impact, Possible Challenges and Proposed Solutions to Using Electronic Health Records (EHRS) for Research and Policy Shaping in the Region

    Jun 1, 2024, 00:00

  • EE505 Predictive Analysis Comparing Economic and Clinical Consequences of Treatment-related Hepatotoxicity in KRASG12C-mutated Advanced Non-small Cell Lung Cancer (aNSCLC) Patients Treated Post-immunotherapy (IO)

    Jun 1, 2024, 00:00

  • PCR52 Early Real-World Experience With Abrilada Within the Canadian Patient Population

    Jun 1, 2024, 00:00

  • HSD99 Impact of Pink October in Mammographic Screening in a Health Care Plan in Brazil

    Jun 1, 2024, 00:00

  • EE250 Work Productivity Loss Among Adults Aged 18–64 Years With Osteoarthritis in the United States: 2016-2020

    Jun 1, 2024, 00:00

  • HPR123 Impact of Mandated Use of the Texas Prescription Monitorsing Program on Carisoprodol Dispensing in Texas

    Jun 1, 2024, 00:00

  • EE289 Cost-Effectiveness Analysis of Blinatumomab for Advanced Acute Lymphoblastic Leukemia in Japan

    Jun 1, 2024, 00:00

  • SA7 Outcomes With Novel Therapies for Relapsed or Refractory Follicular Lymphoma: A Targeted Literature Review

    Jun 1, 2024, 00:00

  • EE72 Economic Burden of Long-Term Care (LTC) in Patients with Advanced Huntington's Disease (HD) and the Impact on Caregivers in North America: A Systematic Literature Review (SLR)

    Jun 1, 2024, 00:00

  • RWD5 A Novel Predictive Model for Agitation in Alzheimer’s Dementia Using Administrative Claims Data

    Jun 1, 2024, 00:00

  • Addressing Confounding in Real-World Evidence Studies

    Jun 1, 2024, 00:00

  • EE328 Direct Medical Costs in Patients with Non-Metastatic Castration Resistant Prostate Cancer (nmCRPC) in Colombia

    Jun 1, 2024, 00:00

  • AI and Machine Learning to Address Equity and Fairness in Healthcare

    Jun 1, 2024, 00:00

  • EE16 Economic Analysis of the Impact of Delandistrogene Moxeparvovec Gene Therapy on Work Opportunity in Caregivers of Individuals with Duchenne Muscular Dystrophy

    Jun 1, 2024, 00:00

  • MT26 HTA Requirements for Medical Technologies in Canada

    Jun 1, 2024, 00:00

  • CO206 The Clinical and Financial Impact of Sustained Annual Wellness Visit Engagement in the Blue Cross and Blue Shield of Louisiana Medicare Advantage Population

    Jun 1, 2024, 00:00

  • PCR46 A Qualitative Exploration of Patient and Healthcare Provider Perspectives on Oxybate Treatments for Narcolepsy

    Jun 1, 2024, 00:00

  • EE457 Economic Burden Impact of Thyroid Eye Disease in the United Arab Emirates

    Jun 1, 2024, 00:00

  • RWD86 Impact of Population Aging on the Colombian Health System: A Real-World Data Analysis

    Jun 1, 2024, 00:00

  • EE153 Cost-Minimization of Oral Valganciclovir Vs Intravenous Ganciclovir for Cytomegalovirus Prophylaxis in Renal Transplant Recipients

    Jun 1, 2024, 00:00

  • RWD23 Development of an Optimal Corticosteroid Dosage Regimen for the Management of Acute Respiratory Distress Syndrome: A Sequential Explanatory Mixed Method Approach

    Jun 1, 2024, 00:00

  • MSR3 Cough, Dyspnea, Chest Pain or a Composite? Analysis of Key Symptoms in Metastatic Non-Small Cell Lung Cancer (mNSCLC) Clinical Trials

    Jun 1, 2024, 00:00

  • P40 Caregivers’ Stated and Revealed Preferences for Antipsychotic Medication Use Among Youth: A Discrete Choice Experiment of Benefit-Risk Trade-Offs

    Jun 1, 2024, 00:00

  • MSR61 Perceptions of the Feasibility of AI-Based Machine Translation for Linguistic Validation

    Jun 1, 2024, 00:00

  • RWD70 Dental Complication Burden in Patients with Phosphorus Metabolism and Phosphatase Disorders: Insights from a 14-Year Nationwide Longitudinal Retrospective Study in South Korea

    Jun 1, 2024, 00:00

  • HPR30 Variation in per Beneficiary Prescription Utilization and Spending By Race/Ethnicity in Medicare and Medicaid Insurance Claims

    Jun 1, 2024, 00:00

  • HSD73 Neoadjuvant Adjuvant Therapy for Early-Stage/Resectable Non-Small Cell Lung Cancer (NSCLC): Physician Practices, Therapy Choice, and Challenges Among US Oncologists

    Jun 1, 2024, 00:00

  • EPH119 Public Health Results in the Department of Bolívar, Colombia: An Analysis of Indicators in 2023

    Jun 1, 2024, 00:00

  • P64 Which Healthcare-System Factors Influence Reimbursement Success Rates? A Multi-Country Analysis of Reimbursement Decisions in 2023

    Jun 1, 2024, 00:00

  • RWD105 The Clinical and Economic Burden of Woman with Endometriosis (EM)

    Jun 1, 2024, 00:00

  • RWD151 Knowledge Management Tool: A Large Language Model-Based Search Engine

    Jun 1, 2024, 00:00

  • CO144 Association of All-Cause and Cause-Specific Mortality with High-Risk NAFLD/NASH in US Adults, NHANES III (1988-1994) Linked to Mortality Data through 2019

    Jun 1, 2024, 00:00

  • HPR58 Mapping Medicaid: A Comparative Analysis of State-Level Racial and Ethnic Data Collection to Federal Guidelines

    Jun 1, 2024, 00:00

  • MT4 The Trend, Outcomes, and Resources Utilization of Surgical Staplers Used in Patients Treated with Robotic Gastric Sleeve Procedures

    Jun 1, 2024, 00:00

  • HSD60 Self-Reported Pain Severity and Opioid Utilization in Adult Patients with Spine-Related Problems

    Jun 1, 2024, 00:00

  • MSR64 Using Large Language Models To Extract PD-L1 Testing Details From Electronic Health Records

    Jun 1, 2024, 00:00

  • EE154 The Economic Burden of HER2+ Breast Cancer and the Epidemiological Economic Impact of Targeted Therapies in the Dominican Republic

    Jun 1, 2024, 00:00

  • EE301 Economic Burden of Disease Recurrence in Elderly Patients With High-Risk Endometrial Cancer (HR-EC) Receiving Adjuvant Therapy (AT)

    Jun 1, 2024, 00:00

  • MT44 Handheld Robotically Assisted Primary Unilateral Total Knee Arthroplasty (R-TKA) Demonstrates Lower Short-Term Costs and Length of Stay Compared to Conventional Instrumentation TKA (C-TKA)

    Jun 1, 2024, 00:00

  • EE14 Cost of Care Comparison of Elranatamab-bcmm and Teclistamab-cqyv in Adult Patients with Relapsed or Refractory Multiple Myeloma (RRMM)

    Jun 1, 2024, 00:00

  • CO174 Baseline Characteristics of Patients with Asthma and Prior Oral Systemic Corticosteroid Use Initiating Dupilumab in a Real-World Registry (RAPID)

    Jun 1, 2024, 00:00

  • PCR56 Are Limitations in Physical Function Relevant and Important Concepts To Assess in Patients on Antithrombotic Therapy for Cardiovascular Conditions?

    Jun 1, 2024, 00:00

  • EPH59 A Systematic Review on the Health Equity Disparities in Lupus Treatment: Medicaid Vs. Private Payer Outcomes

    Jun 1, 2024, 00:00

  • EPH42 Evaluating the Public Health Impact of Dengue Vaccination in Indonesia: A Dynamic Transmission Modeling Assessment amidst Uncertainties in the Implementation Strategies

    Jun 1, 2024, 00:00

  • PCR147 Breaking a Vicious Cycle: Including the Patient Perspective for Meaningful Psoriasis Severity Evaluation Towards Broader Recognition of Burden and Unmet Needs

    Jun 1, 2024, 00:00

  • EPH178 Representing Thyroid Cancer Epidemiology in the US Over Time: A Microsimulation Modeling Approach Incorporating Temporal Differences in Thyroid Ultrasound Utilization by Sex and Age

    Jun 1, 2024, 00:00

  • EE426 Cost-Comparison Analysis of Non-Invasive Testing Strategies for Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Veteran Population

    Jun 1, 2024, 00:00

  • HPR38 Estimating the Outcome Disparities in BIPOC and Economically-Disadvantages Patients With Systemic Lupus Erythematosus (SLE)

    Jun 1, 2024, 00:00

  • PCR98 Suboptimal Dosing and Discontinuation of Antifibrotic Agents in Patients with Idiopathic Pulmonary Fibrosis (IPF)

    Jun 1, 2024, 00:00

  • EE284 Cost-Effectiveness Analysis of Larotrectinib and Entrectinib for Adult Patients with NTRK Gene Fusion-Positive Breast Cancer

    Jun 1, 2024, 00:00

  • RWD30 Ways To Minimize Data Quality Headaches in Migraine Research

    Jun 1, 2024, 00:00

  • EPH123 Incorporating Social Determinants of Health Into Transmission Modeling of COVID-19 Vaccine in the US: A Scoping Review

    Jun 1, 2024, 00:00

  • CO202 Relationship between Loss of Ambulation (LoA) and Timing of Pulmonary Outcomes Among Boys with Duchenne Muscular Dystrophy (DMD)

    Jun 1, 2024, 00:00

  • EE440 Cost-Effectiveness of Adjuvanted RSVPreF3 Vaccination in Adults Aged 50-59 Years With Cardiopulmonary Diseases in the United States

    Jun 1, 2024, 00:00

  • HSD92 Clinical Outcomes of Patients With Obesity in a US Employer-Funded Medical Weight Management Program: A Pilot Study

    Jun 1, 2024, 00:00

  • EE18 Burden of Illness for Adults With Chronic Inflammatory Demyelinating Polyneuropathy in the United States

    Jun 1, 2024, 00:00

  • EPH33 Trend of Mortality By Asthma in Colombia, 1998 - 2021

    Jun 1, 2024, 00:00

  • MSR63 Improving Efficiency in Analysis of Real-World Data with an Automated Machine Learning Tool

    Jun 1, 2024, 00:00

  • CO172 Indirect Treatment Comparison of Efficacy and Safety of Capivasertib-Fulvestrant Versus Alpelisib-Fulvestrant for PIK3CA-Altered, HR-Positive, Advanced Breast Cancer after Disease Progression Following Endocrine-Based Therapy

    Jun 1, 2024, 00:00

  • HSD112 Product Entry Sequence and Priority of Follow-on Drug Use: A Case Study of Second-Generation Antipsychotics with Long-Acting Injections

    Jun 1, 2024, 00:00

  • EE466 Implementing the Generalized Risk-Adjusted Cost-Effectiveness (GRACE) Model for Sickle-Cell Disease: A Case Study

    Jun 1, 2024, 00:00

  • EE462 Healthcare Utilization in Non-Alcoholic Steatohepatitis (NASH) Patients with Elevated Nafld Activity Score (NAS): Impact of Fibrosis Levels

    Jun 1, 2024, 00:00

  • Methodological Statistical Research

    Jun 1, 2024, 00:00

  • EE168 Avoidable Costs in Patients with Metastatic Hormone Sensitive Prostate Cancer (mHSPC) Treated with Darolutamide

    Jun 1, 2024, 00:00

  • EE427 The Reduction in Medical and Care Costs for Diseases Associated with Being Bedridden in Rural Residents in Japan

    Jun 1, 2024, 00:00

  • EPH158 Using Data to Develop Precision Medicine Approaches to Public Health Initiatives

    Jun 1, 2024, 00:00

  • CO190 Lumbar Spine Problems Caused By Hyperextension and It's Prevention, As Well As Balance Development in Rhythmic Gymnasts

    Jun 1, 2024, 00:00

  • EE61 Cost-Effectiveness of 20-Valent Pneumococcal Conjugate Vaccine in Mexican Adults Population

    Jun 1, 2024, 00:00

  • EE488 Cost-Effectiveness Analysis of Faricimab and Others Treatment Schemes for Diabetic Macular Edema and Age-Related Macular Degeneration

    Jun 1, 2024, 00:00

  • EPH10 Serotype Distribution Among Streptococcus Pneumoniae Isolates in Puerto Rico (PNEUMOSER STUDY)

    Jun 1, 2024, 00:00

  • EE297 Pricing Strategies and Trends of FDA Approved NSCLC Therapies From 2018 to 2023

    Jun 1, 2024, 00:00

  • RWD164 Evidence Gap Analysis of the Burden of Disease in Thyroid Eye Disease

    Jun 1, 2024, 00:00

  • HPR117 Emergency Room Utilization Among Multiple Sclerosis Patients Treated with Disease-Modifying Therapy in a Real-World Hybrid Claims Database

    Jun 1, 2024, 00:00

  • CO179 The Association Between Social Determinants of Health, COVID-19, and Incidence of De Novo Depression Following Traumatic Brain Injury

    Jun 1, 2024, 00:00

  • PCR121 Optimizing Drug Value and Access Using Implementation Science

    Jun 1, 2024, 00:00

  • RWD187 The Use of a Large Epidemiological Surveillance Dataset (SIVEP-Gripe) for the Generation of Scientific Evidence in Brazil on COVID-19: A Literature Review

    Jun 1, 2024, 00:00

  • EPH89 Telehealth Utilization Among Children with Autism Spectrum Disorder in Employer-Sponsored Plans, 2019–2022

    Jun 1, 2024, 00:00

  • EE385 Changes in Direct Costs of Breast Cancer in Colombia From 2011 to 2022

    Jun 1, 2024, 00:00

  • EE295 Economic Burden Associated With Managing Patients With Sickle Cell Disease Receiving Frequent Red Blood Cell Transfusions in the United States

    Jun 1, 2024, 00:00

  • EPH171 A Qualitative Survey Analysis for Understanding COVID-19 Vaccine Hesitancy in the United States

    Jun 1, 2024, 00:00

  • EPH7 Examination of Weight-Related Coding Practices in Administrative Claims: Implications for Future Analyses

    Jun 1, 2024, 00:00

  • CO147 The Potential Long-Term Comparative Effectiveness of Larotrectinib Vs. Entrectinib for Treatment of Metastatic Fusion-Positive Cancers in Children and Young Adults

    Jun 1, 2024, 00:00

  • HSD74 COVID-19's Impact on Healthcare Access for Arthritis Patients: Insights From the 2020 Medical Expenditure Panel Survey

    Jun 1, 2024, 00:00

  • PT45 Patient Perspective in Endometriosis and Clinical Trial Barriers

    Jun 1, 2024, 00:00

  • RWD44 Key Components of a Strong Real World Data Quality and Relevance Package for Regulatory or Health Technology Assessment Submission

    Jun 1, 2024, 00:00

  • PCR70 Diagnostic Journey, Seizure Burden, and Quality of Life Among Patients With CDKL5 Deficiency Disorder Using Real-World Data

    Jun 1, 2024, 00:00

  • CO117 Factors Associated with Biologic Treatment De-Escalation in Patients with Crohn’s Disease

    Jun 1, 2024, 00:00

  • MSR90 Incorporating Patient Preferences Into Mathematical and Statistical Models in Health Economics: A Taxonomy of Approaches

    Jun 1, 2024, 00:00

  • PCR99 Mixed Methods Research to Understand Disease Burden and Unmet Need in HDFN and FNAIT

    Jun 1, 2024, 00:00

  • HPR50 How Do We Define Value in Health? Well, That Depends

    Jun 1, 2024, 00:00

  • HSD44 Association of Penicillin Allergy Documentation and First-Line Penicillin Prescribing for Common Infections in Primary Healthcare Facilities in Beijing

    Jun 1, 2024, 00:00

  • HSD30 Incidence of Platinum-Resistant, Stage III/IV Ovarian Cancer Patients in the US: A Mixed Source Estimation Approach

    Jun 1, 2024, 00:00

  • RWD6 Effect of Selumetinib Treatment on Pain Medication Utilization in Pediatric Patients: A US Claims Database Analysis

    Jun 1, 2024, 00:00

  • EPH70 Real-World Second-Line Treatment Pattern and Disease Burden of Patients With Unresectable or Advanced Hepatic Carcinoma in China: A Retrospective Database Study

    Jun 1, 2024, 00:00

  • EE107 Long-Term Cost-Effectiveness of iGlarLixi Versus IDegLira in Patients With Uncontrolled Type 2 Diabetes Treated With Basal Insulin or Oral Antidiabetic Drug in China

    Jun 1, 2024, 00:00

  • EE272 Treating Patients With Non-Valvular Atrial Fibrillation With Apixaban Provides Substantial Consumer Value and Surplus Compared With Warfarin and Rivaroxaban

    Jun 1, 2024, 00:00

  • MSR59 Advancing Systematic Literature Reviews: The Integration of AI-Powered NLP Models in Data Collection Processes

    Jun 1, 2024, 00:00

  • RWD114 Economic Burden, Treatment Utilization, and Medication Adherence of Post-Traumatic Stress Disorder (PTSD) Patients: A Retrospective Commercial and Medicare Part B Insurance Claims Analysis

    Jun 1, 2024, 00:00

  • P30 Semi-Markov Model (sMM) Versus Trial-Level Surrogacy to Predict Overall Survival (OS) for Adjuvant Treatment of Muscle-Invasive Urothelial Carcinoma (MIUC) with Chemotherapy

    Jun 1, 2024, 00:00

  • HPR74 Challenges Encountered When Using Required Machine-Readable Files From the 2022 Transparency in Coverage Rule: A Blue Cross and Blue Shield of Louisiana Case Study

    Jun 1, 2024, 00:00

  • P3 Longitudinal Analyses of Healthcare Resource Utilization and Costs Among Patients with Obstructive Hypertrophic Cardiomyopathy

    Jun 1, 2024, 00:00

  • PCR198 Assessing the Additional Value of Negative Multi-Cancer Early Detection (MCED) Tests: Results from an Online Survey of the General Population

    Jun 1, 2024, 00:00

  • EE261 Costs and Outcomes Associated with COVID-19 Hospitalisation in the South African Public-Sector during the First-Wave

    Jun 1, 2024, 00:00
  • 1
  • 2
  • 3
  • 4
  • 5 (current)
  • 6
  • 7
  • 8
  • 9
  • 10
  • »